Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Other Non Operating Income (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Other Non Operating Income for 5 consecutive years, with $231634.0 as the latest value for Q3 2017.

  • On a quarterly basis, Other Non Operating Income rose 622.41% to $231634.0 in Q3 2017 year-over-year; TTM through Sep 2017 was $402881.0, a 404.88% increase, with the full-year FY2017 number at $651212.0, up 528.3% from a year prior.
  • Other Non Operating Income was $231634.0 for Q3 2017 at Crescent Biopharma, up from $102079.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $231634.0 in Q3 2017 to a low of -$104.0 in Q2 2013.
  • A 5-year average of $30019.6 and a median of $4827.0 in 2014 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 31171.43% in 2014, then tumbled 38.12% in 2015.
  • Crescent Biopharma's Other Non Operating Income stood at $14.0 in 2013, then surged by 31171.43% to $4378.0 in 2014, then surged by 33.01% to $5823.0 in 2015, then skyrocketed by 409.58% to $29673.0 in 2016, then soared by 680.62% to $231634.0 in 2017.
  • Per Business Quant, the three most recent readings for CBIO's Other Non Operating Income are $231634.0 (Q3 2017), $102079.0 (Q2 2017), and $39495.0 (Q1 2017).